The efficacy and mechanism of tucatinib

Tucatinib, also known as tucatinib, is an oral small molecule tyrosine kinase inhibitor (TKI), mainly used to treat HER2 positive breast cancer. It brings new breakthroughs in the field of breast cancer treatment by inhibiting the signaling of HER2 receptors and blocking the proliferation and metastasis of tumor cells.

Tucatinib mainly acts on the human epidermal growth factor receptor2 (HER2) signaling pathway. HER2 is a protein closely related to the growth and survival of cancer cells. It is overexpressed in some cancer cells and promotes the proliferation, survival and metastasis of cancer cells. Tucatinib can selectively bind to the HER2 receptor and block its downstream signaling, thus inhibiting the growth and division of cancer cells. In addition, tucatinib can also enhance the immune system's ability to recognize and attack cancer cells, exerting a synergistic anti-tumor effect.

A number of clinical trials, especially the HER2CLIMB trial, have confirmed the significant efficacy of tucatinib in prolonging the survival of HER2 positive breast cancer patients. In the HER2CLIMB trial, tucatinib was combined with trastuzumab and capecitabine to treat patients with HER2 -positive metastatic breast cancer compared with a control group who received only trastuzumab and capecitabine. Compared with PFS, the median progression-free survival (PFS) of the combination treatment group reached 7.8 months, while that of the control group was only 5.6 months. At the same time, the median overall survival (OS) of the combination treatment group was extended to 21.9 months, while that of the control group was 17.4 months. These data show that the addition of tucatinib significantly extended patient survival.

HER2 Positive breast cancer is prone to brain metastasis, and traditional macromolecule drugs cannot easily penetrate the blood-brain barrier, so treatment options for patients with brain metastasis are relatively limited. With its small molecule design and ability to penetrate the blood-brain barrier, tucatinib is particularly outstanding in the treatment of HER2-positive breast cancer with brain metastasis. Data from the HER2CLIMB trial show that for patients with existing brain metastases, the median PFS in the tucatinib combination treatment group was 7.6 months, compared with only 5.4 months in the control group. This shows that tucatinib also has significant efficacy in patients with brain metastases.

In addition to prolonging survival, tucatinib also improves patients' quality of life by effectively controlling disease progression and reducing symptom burden. Clinical trial data show that patients treated with tucatinib have a reduced risk of disease progression. The extension of PFS provides patients with a longer stable period and effectively curbs the progression of the disease. In addition, the oral form of tucatinib also makes it more convenient for patients to take, reducing the inconvenience of hospitalization and treatment.

Tucatinib is primarily approved for the treatment of HER2 -positive advanced or metastatic breast cancer, particularly in patients who have experienced at least two anti-HER2 treatment regimens. The recommended dose is 300 mg twice daily, taken orally in combination with trastuzumab and capecitabine until disease progression or unacceptable toxicity. Advise patients to swallow tablets whole and not to chew, crush or split. Patients take tucatinib approximately 12 hours apart each day, preferably on an empty stomach.

Although tucatinib works well in treatingHER2positive breast cancer, it can still cause some side effects. Common side effects include gastrointestinal symptoms such as diarrhea, nausea, and vomiting, as well as systemic symptoms such as fatigue and headache. In addition, some patients may also develop abnormal liver function, rash, hand-foot syndrome, etc. These side effects are usually mild to moderate and can be relieved by adjusting the dose or giving other medications.

In order to ensure safe medication use for patients, doctors need to monitor patients closely, adjust medication dosages in a timely manner or take other measures to manage adverse reactions. For example, for severe diarrhea symptoms, medication needs to be stopped immediately and active treatment is required; for patients with abnormal liver function, liver function indicators need to be monitored regularly and the treatment plan adjusted according to the specific situation.

References:

1.https://www.tukysa.com/

2.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer